玻璃体腔注射康柏西普治疗湿性年龄相关性黄斑变性的早期mfERG变化  

Early multifocal electroretinography findings after intravitreal Conbercept in the treatment of wet age-related macular degeneration

作　　者：黄定国[1] 郑建龙[1] 林国乔[1] 陈伟奇[1] Ding-Guo Huang;Jian-Long Zheng;Guo-Qiao Lin;Wei-Qi Chen(Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong,Shantou 515041,Guangdong Province,China)

机构地区：[1]汕头大学.香港中文大学联合汕头国际眼科中心,中国广东省汕头市515041

出　　处：《国际眼科杂志》2018年第9期1692-1695,共4页International Eye Science

基　　金：广东省医学科学技术研究基金项目(No.A2016550)~~

摘　　要：目的:利用多焦视网膜电图(mfERG)评价玻璃体腔注射康柏西普的湿性年龄相关性黄斑变性(age-related macular degeneration,ARMD)患者视网膜功能的早期变化。方法:经眼底荧光血管造影确诊为湿性ARMD患者接受玻璃体腔注射康柏西普眼用注射液(0.05mL/0.5mg),记录注射前及注射后1mo的最佳矫正视力及mfERG各环N1、P1波潜伏期及P1波振幅密度。结果:共20例20眼患者纳入研究,平均LogMAR视力从注射前0.80±0.48提高到注射后0.65±0.50(P<0.001),环1平均振幅密度从注射前39.59±16.60nV/deg^2提高到注射后的53.81±20.41nV/deg^2(P=0.006),振幅密度的改变与视力的改变呈正相关(r=-0.776,P<0.001)。结论:对于湿性ARMD患者玻璃体腔注射康柏西普短期内能改善黄斑中心凹的功能。·AIM:To evaluate the early changes of retinal function in patients with wet age-related macular degeneration(ARMD)after intravitreal Conbercept treatment by multifocal electroretinography(mfERG).·METHODS:Wet ARMD patients diagnosed by fundus fluorescein angiography and received intravitreal injection of Conbercept(0.05mL/0.5mg)were included.Best corrected visual acuity(BCVA),incubation of N1,P1 and amplitude of P1 in mfERG test were recorded before and 1mo after treatment.·RESULTS:Twenty patients(20 eyes)were enrolled in total.The mean BCVA was 0.80±0.48 LogMAR at baseline and improved to 0.65±0.50 LogMAR after treatment(P<0.001).Mean P1 amplitude density of the mfERG Ring 1 increased from 39.59±16.60nV/deg2 to 53.81±20.41nV/deg2(P=0.006).The change in visual acuity was positively correlated with the change in P1 amplitude density of Ring 1(r=-0.776,P<0.001).·CONCLUSION:Intravitreal conbercept injection can improve the central retinal function of wet ARMD patients in the short term.

关 键 词：多焦视网膜电图 康柏西普眼用注射液 湿性年龄相关性黄斑变性 

分 类 号：R774.5[医药卫生—眼科]